닥플 플러스
KSSG Annual Symposium 2026
대한간학회
연수평점 :6점
오프라인
주관
대한간학회 / 대한지방간연구회
교육일자
2026-08-29
수강료
50,000원
교육형태
오프라인
등록일시
2026-07-08
교육시간
6시간
연수평점
6점
장소
서울특별시 유한양행 윌로우하우스 3층 뉴스퀘어홀
교육종류
내과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-08-29 | 08:55~09:00 | 개회사 | 전대원(대한간학회 지방간연구회 회장) | - |
| 2026-08-29 | 09:00~09:05 | 환영사 | 임영석(대한간학회 이사장) | - |
| 2026-08-29 | 09:05~09:25 | Background and Emerging Issues in MASLD and cardiovascular-kidney-metabolic syndrome era | 김태형(고려의대) | - |
| 2026-08-29 | 09:25~09:45 | Alcohol Exposure in MASLD: Limits of Current Thresholds and Emerging Approaches | 김정희(한림의대) | - |
| 2026-08-29 | 09:45~10:05 | Cardiometabolic Risk in MASLD: Beyond Current Criteria Toward Prognostic Refinement | 유성환(연세의대) | - |
| 2026-08-29 | 10:05~10:25 | Beyond Cardiometabolic Risk in MASLD: Kidney Disease and Prognostic Implications | 조영윤(중앙의대) | - |
| 2026-08-29 | 10:25~10:40 | 차담과 휴식 | - | - |
| 2026-08-29 | 10:40~11:00 | Genetic Susceptibility in MASLD: From PNPLA3 to Polygenic Risk | 안지현(한양의대) | - |
| 2026-08-29 | 11:00~11:20 | MetALD: Alcohol–Metabolic Interaction and Fibrosis Risk | 서원효(이화의대 약대) | - |
| 2026-08-29 | 11:20~11:40 | Sarcopenia and Myokines: Systemic Drivers of MASLD Progression | 박하나(건국의대) | - |
| 2026-08-29 | 11:40~12:00 | Emerging Therapies for MASH: Beyond Resmetirom, Incretin, and FGF21 | 손원(성균관의대) | - |
| 2026-08-29 | 12:00~12:10 | Panel Discussion | -(-) | - |
| 2026-08-29 | 12:10~13:00 | 점심시간 | -(-) | - |
| 2026-08-29 | 13:00~13:20 | Biomarker Updates in MASLD: ELF, M2BPGi, Agile, Multi-omics, and AI-driven markers | Yuya Seko(Kyoto Prefectural Univ Med) | - |
| 2026-08-29 | 13:20~13:40 | Screening and risk stratification of MASLD using transient elastography | 김승업(연세의대) | - |
| 2026-08-29 | 13:40~14:00 | 2D Shear Wave Elastography-based Risk Stratification in Patients with MASLD | Satoshi Oeda(Saga Univ) | - |
| 2026-08-29 | 14:00~14:20 | Clinical Insights from Biopsy-Based MASLD Cohorts in Korea and Japan | Hideki Fujii김순선(Osaka Metropolitan Univ아주의대) | - |
| 2026-08-29 | 14:20~14:35 | 차담과 교류 | - | - |
| 2026-08-29 | 14:35~14:55 | Biopsy free NIT-Guided Treatment in MASLD: Determining Treatment Eligibility and Monitoring Response | Hirokazu Takahashi(Saga Univ) | - |
| 2026-08-29 | 14:55~15:15 | FGF-21 Based Therapies in MASLD | 장세영(경북의대) | - |
| 2026-08-29 | 15:15~15:35 | Incretin-Based Therapies in MASLD: From GLP-1 Monotherapy to Multi-Agonists and Oral Agents | 송정은(대구가톨릭의대) | - |
| 2026-08-29 | 15:35~15:55 | SGLT2 inhibitor Based Therapies in MASLD | Dan Nakano(Kurume Univ) | - |
| 2026-08-29 | 15:55~16:15 | Extrahepatic Outcomes of Incretin-Based Therapy in MASLD: Cardiovascular, Renal, and Metabolic Implications | 김남훈(고려의대) | - |
| 2026-08-29 | 16:15~16:25 | Panel Discussion | - | - |
| 2026-08-29 | 16:25~16:30 | 폐회사 | 윤아일린(대한간학회 지방간연구회 학술이사) | - |
문의처
담당자
대한간학회
연락처
02-703-0051
이메일
kasl@kams.or.kr